Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The report highlights that the pharmaceutical sector is showing resilience, with a focus on capturing opportunities from companies that can deliver on their growth potential. The report suggests that investors should continue to allocate to pharmaceutical bottom assets as fund holdings have returned to a low level [3][10] - The report indicates that the A-share funds' top ten holdings in the pharmaceutical sector account for 9.15%, a decrease of 1.93 percentage points from the previous period. Excluding pharmaceutical funds, the allocation drops to 3.43%, down 1.39 percentage points [3][10] - The report emphasizes the strong performance of certain pharmaceutical companies, particularly in innovative drugs and upstream life sciences, with notable profit growth forecasts for companies like Zhaoyan New Drug and Kangchen Pharmaceutical [3][10] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 6.66% compared to the CSI 300's 1.57% since the beginning of 2026, indicating a 5.10 percentage point advantage [14] - Recent performance shows a mixed trend, with pharmaceutical commercial, traditional Chinese medicine, and medical devices showing positive growth, while chemical pharmaceuticals and medical services have declined [10][14] Valuation Metrics - The current valuation of the pharmaceutical sector is at 23.3 times PE based on 2026 earnings forecasts, which is a premium of 11.3% compared to the overall A-share market (excluding financials) at approximately 21.0 times PE [17] - Using the TTM valuation method, the pharmaceutical sector is valued at 30.3 times PE, which is below its historical average of 34.9 times PE, indicating a relative premium of 11.2% over the broader market [17] Recommended Stocks - Key recommended stocks include WuXi Biologics, Sangfor Technologies, Tigermed, and others, with an average increase of 13.41% in January, outperforming the pharmaceutical sector by 6.74 percentage points [26][27] - The report notes that the top ten pharmaceutical stocks held by public funds include companies like Hengrui Medicine and WuXi AppTec, with a strong preference for innovative drugs and leading players in niche markets [3][10]

Core Viewpoint - The A-share market has shown a rebound in trading activity, with transaction volume exceeding 3 trillion yuan, indicating strong internal confidence and capital inflow amidst domestic asset scarcity and expectations of RMB appreciation [1][29]. Market Structure and Trends - The market structure has shifted compared to late last year and early this year, with increased activity in the real estate chain, resource products, and price increase chains, reflecting the inflow of medium to low-risk preference capital [1][6][39]. - Recent signals of expanding domestic demand policies have emerged, with expectations of policy enhancements, particularly in real estate prices, infrastructure investment, and service consumption, which are key areas of focus for medium to low-risk preference capital [1][39]. - The expansion of cyclical stocks indicates rising market confidence in re-inflation, with performance spreading from non-ferrous metals to chemicals, building materials, and coal, suggesting strong confidence in the PPI recovery trend this year [1][11][42]. Sector Performance - The small-cap stocks have outperformed large-cap stocks, with indices like the CSI 500 and CSI 1000 showing significant gains of 4.34% and 4.04% respectively, indicating increased participation and liquidity support for small-cap stocks [5][35]. - The real estate chain and cyclical resource products have benefited from warming policy expectations and re-inflation, with recent policy announcements aimed at reversing funding dilemmas in the real estate sector [39][42]. - The communication sector has faced declines, raising concerns about the sustainability of previously favored stocks, as institutional holdings in this sector have not consistently yielded excess returns [19][44]. Investment Focus - Key sectors to watch include semiconductors, non-ferrous metals, computing, media, chemicals, and military industries, with themes such as commercial aerospace, AI applications, robotics, controllable nuclear fusion, intelligent driving, and innovative pharmaceuticals being highlighted [31][37]. - The price increase chain remains a significant investment focus, particularly in areas experiencing supply-demand mismatches, such as AI hardware and upstream raw materials like lithium carbonate and PTA [20][21][23].

Group 1: Stock Market Trends - A-shares saw significant gains with over a hundred stocks hitting the daily limit, and 27 companies are projected to have over 50% upside potential, focusing on smart driving and innovative pharmaceuticals [2][7] - Six stocks have already doubled in price this year, with Zhizhi New Materials showing a remarkable increase of 256.35% [2][7] - The oil shipping sector has shown strong performance, with companies like China Merchants Energy and COSCO Shipping Energy reaching historical highs, indicating a potential new super cycle in the industry [2][7] Group 2: Technology and Innovation - The photovoltaic sector in A-shares exploded, with over 30 stocks hitting the daily limit following Elon Musk's support for space-based solar power, which is expected to create a demand of nearly 10GW [3][8] - AI marketing is gaining traction, with the market size expanding significantly; leading companies like Zhejiang Wenhu Interconnect have seen stock prices rise nearly 60% in January [5][10] Group 3: Economic Indicators and Future Outlook - Upcoming economic data includes the January PMI report and the Federal Reserve's interest rate decision, with expectations of rates remaining unchanged [4][9] - The Shanghai Composite Index has experienced a rare nine consecutive declines, marking the second occurrence in history, but historical data suggests a high probability of rebound following such streaks [4][10] - A significant amount of capital is expected to flow into the stock market as a large volume of fixed-term deposits matures this year [4][10]

Core Insights - The public fund industry in China achieved a record profit of 2.6 trillion yuan in 2025, recovering from a cumulative loss of 1.87 trillion yuan from 2022 to 2023 [1][2] - Despite a loss of approximately 110 billion yuan in Q4 2025, the overall annual performance marked a significant recovery for the industry [2][3] Fund Performance - In Q4 2025, public funds reported a total loss of 1,097.65 billion yuan, ending a streak of seven consecutive profitable quarters [2][3] - Equity funds were the hardest hit, with a combined loss of 1,306.91 billion yuan in Q4, while mixed funds lost 499.56 billion yuan [3][4] - For the entire year, equity funds still managed to generate a profit of 1.99 trillion yuan, despite the Q4 downturn [4] Product Categories - QDII funds and FOF funds also faced losses in Q4, amounting to 710.47 billion yuan and 2.12 billion yuan respectively, but ended the year with profits of 1,125.22 billion yuan and 186.38 billion yuan [4] - Fixed-income products, including bond and money market funds, contributed significantly to profits, with bond funds earning 580.81 billion yuan and money market funds 443.13 billion yuan [4] Fund Company Performance - Among 167 fund companies, 108 reported positive profits, with over 60% achieving profitability [5] - Notable performers included Guotou Ruijin Fund, which led the industry with a profit of 72.82 billion yuan [5] Stock Holdings Adjustments - Public funds increased their holdings in 83 new stocks by the end of Q4 2025, with a focus on technology and cyclical sectors [7] - Ningde Times remained the top holding stock, despite a reduction of 1,993 million shares, while Zhongji Xuchuang became the most held stock among active funds [10][11] Sector Focus - The communication sector, particularly in optical modules, saw increased institutional investment, with Zhongji Xuchuang and Xinye Technology becoming top holdings [10] - The top three sectors for public fund investments were electronics, power equipment, and communication, with significant capital allocated to these areas [13]

Market Performance - After a six-day decline, the Hong Kong Stock Connect Innovation Drug ETF (520880) rebounded on January 23, rising over 2% at one point and closing up 1.53% with a trading volume of 348 million yuan [1][6] - Major constituent stocks such as Cloudtop New Drug led the gain with an 8.2% increase, while other key stocks like Kangfang Biotech and Shiyao Group also saw positive performance [1][6] Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued a document promoting high-quality development in the pharmaceutical retail sector, encouraging innovative drugs and reference preparations to enter retail pharmacy sales channels [3][9] - This policy is expected to provide a pathway for high-value innovative drugs, such as CAR-T, to fill the insurance coverage gap through commercial insurance directories [3][9] - The insurance industry association estimates that by 2025, the total compensation amount for innovative drugs and devices from commercial health insurance will reach approximately 14.7 billion yuan, with a compound annual growth rate of 70% over four consecutive years [3][9] Industry Trends - At the recent JPM conference, Chinese pharmaceutical companies showcased technological breakthroughs in areas such as ADC, IO dual antibodies, and GLP-1, moving towards global markets through licensing and collaborative development [3][9] - According to CITIC Securities, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation effectiveness [3][9] Investment Opportunities - The Hong Kong Stock Connect Innovation Drug ETF (520880) is highlighted as a high-elasticity T+0 investment tool, with its index featuring three unique advantages: 1. Purely innovative drugs with 100% purity, covering companies focused on drug development [5][11] 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5][11] 3. Enhanced risk control through forced de-weighting of less liquid constituent stocks [5][11] Constituent Stocks - The top ten constituent stocks of the Hong Kong Stock Connect Innovation Drug ETF (520880) have a combined weight of 73.41%, showcasing significant leadership in the sector [6][12] - Notable stocks include: - Kangfang Biotech (10.49% weight, market cap of 110.9 billion HKD) - Baijie Shenzhou (10.01% weight, market cap of 312 billion HKD) - Shiyao Group (9.97% weight, market cap of 102.1 billion HKD) [6][12]

Group 1 - The economic operation characteristic of "production stronger than demand, external demand better than internal demand" has persisted throughout the year, with macroeconomic indicators showing weakness and a loose monetary policy environment [2][3][6] - Industrial production remains resilient, with December's industrial added value growing by 5.2% year-on-year, exceeding expectations [6][36] - The export amount in December increased by 6.6% year-on-year, also better than expected [6][36] Group 2 - Recent weeks have seen a significant outflow of funds from broad-based ETFs, exceeding 570 billion yuan, while thematic industry ETFs have seen inflows of around 110 billion yuan [3][12][43] - The current market sentiment remains high, with investor sentiment indices indicating a state of excitement, suggesting potential short-term risks [10][40] Group 3 - The focus on investment should be on "technology + resource products," with AI semiconductors and new energy being the core areas of current prosperity [4][35] - Emerging hotspots such as AI applications, space photovoltaics, and innovative pharmaceuticals are continuously catalyzing market interest [4][50][51] Group 4 - The non-ferrous metals industry has the highest forecasted performance rate for 2025, indicating a positive outlook for the sector [5][54] - The South China Metal Index has risen by 12.5% since December, while energy and industrial product indices have only increased by about 7%, suggesting better investment value in the non-ferrous sector [5][54] Group 5 - The AI and semiconductor sectors maintain high levels of prosperity, driven by demand for AI model training and inference, which boosts the associated supply chain [50] - The lithium battery sector is experiencing a recovery, supported by growth in new energy vehicles and energy storage [50][51]

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [5] Core Views - The report emphasizes three main investment themes for 2026: innovation, overseas expansion, and turnaround impulses, with a focus on BD2.0, small nucleic acids, and supply chain (CXO and upstream) [2][3] - The report suggests that the pharmaceutical sector is currently experiencing a rotation in investment focus, particularly in areas such as brain-computer interfaces, AI integration, small nucleic acids, and medical robotics [3] Summary by Sections Public Fund Holdings Update for Q4 2025 - Overall, the market value of public funds holding pharmaceutical stocks has decreased, with a total market value of 217.6 billion yuan, down by 51 billion yuan from the previous quarter [14] - The pharmaceutical sector's allocation in public funds is 7.96%, a decrease of 1.74 percentage points [19] - Chemical preparations remain the most heavily weighted sub-industry, while allocations to medical devices have increased [14][25] Market Review and Analysis - The pharmaceutical and biotechnology index decreased by 0.39% week-on-week, outperforming the CSI 300 index but underperforming the ChiNext index [1] - The total trading volume in the pharmaceutical sector was 554.24 billion yuan, accounting for 4.00% of the total trading volume in the Shanghai and Shenzhen markets [1] Investment Opportunities - The report identifies specific companies for potential investment, including: - CXO and innovative drug companies such as Tigermed, Zhaoyan New Drug, and Hai Si Ke, which have seen significant increases in fund holdings [16][38] - AI innovative drug companies like Jingtai Holdings and small nucleic acid firms such as Frontier Biotech and Yuyuan Pharmaceutical [3][38] - The report also highlights the importance of exploring CROs, essential drugs, and companies showing signs of bottoming out [3]

Strategy Insights - The report highlights a strong spring market driven by active trading in small-cap and thematic investments, with A-share trading volume exceeding 3 trillion, indicating robust market confidence and capital inflow [3][8][22] - The report identifies key themes for investment, including commercial aerospace, AI applications, and the price increase chain, which are expected to attract medium-risk capital [3][22] - The report notes a shift in market structure, with increased focus on real estate, resource products, and price increase chains, reflecting a rebalancing of investment styles [3][22] Market Dynamics - The A-share market has shown a recovery with the Shanghai Composite Index stabilizing and trading volumes rebounding, indicating a restoration of investor confidence [8][13] - Small-cap indices such as the CSI 500 and CSI 1000 have outperformed large-cap indices, suggesting a growing interest in mid and small-cap stocks [11][22] - The report emphasizes the importance of supply-demand mismatches in driving price increases across various sectors, particularly in the semiconductor and resource sectors [3][22][27] Sector Focus - The report suggests that the real estate sector is a critical area for investment, driven by recent policy signals aimed at boosting domestic demand, with leading companies in this sector likely to see revaluation opportunities [3][24] - The cyclical resource sector is expected to benefit from rising PPI and inflation expectations, with a notable increase in prices for industrial metals and chemicals [27][28] - Communication stocks, particularly in the optical communication segment, have faced downward pressure, indicating a need for cautious investment in this area despite overall market optimism [29][41]

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. is seeking to list on the Hong Kong Stock Exchange after previously withdrawing its A-share IPO application, citing the need for international expansion and a more accommodating market for profit fluctuations [1][5]. Financial Performance - The company has shown steady revenue growth but significant profit volatility over the past three years, with revenues of approximately 614.2 million RMB in 2023, 654.5 million RMB in 2024, and 538.0 million RMB in the first nine months of 2025. Net profits were 92.0 million RMB, 26.4 million RMB, and 113.0 million RMB respectively [2][4]. - In 2024, revenue increased by 6.56% year-on-year, but profits dropped by 70% due to a rise in share-based payment expenses and increased sales and administrative costs [2][4]. Business Model and Market Position - Shanghai Shengsheng is a provider of integrated temperature-controlled supply chain services in the pharmaceutical and life sciences sector, focusing on clinical trial temperature control services, which account for over 82% of its revenue [6][10]. - The company is the largest domestic provider of clinical trial temperature-controlled supply chain services and ranks among the top ten globally, serving over 7,000 clients and supporting more than 4400 new drug clinical trial applications [10]. Growth Opportunities - The company plans to use IPO proceeds to expand its operations both domestically and internationally, including the establishment of new regional operational centers and clinical drug warehouses [11]. - The innovative drug sector is experiencing high growth, with a record number of new drug approvals and significant market activity, which may benefit Shanghai Shengsheng's business [8]. Challenges - The company faces high customer concentration, with the top five clients accounting for an increasing percentage of sales, which poses a risk if key client relationships change [5]. - Trade receivables have been growing, indicating potential cash flow pressures, with the turnover days extending from 98 to 105 days [5]. - The company is also exploring new applications for its temperature control technology in advanced manufacturing and renewable energy sectors, but these markets present different challenges and may not yield immediate results [12]. Conclusion - While Shanghai Shengsheng is well-positioned in a growing industry with a solid business model, it must navigate significant operational challenges and market competition to achieve sustainable growth and develop new revenue streams [13].

Core Viewpoint - The A-share market has shown positive momentum with major indices rising, driven by sectors such as perovskite batteries, BC batteries, gallium arsenide, non-ferrous zinc, and photovoltaic glass, leading to over a hundred stocks hitting the daily limit up [1][14]. Group 1: Market Performance - Since the beginning of 2026, the A-share index has increased by over 4%, with the early part of the month supported by policy benefits and liquidity easing, breaking through 4100 points within five trading days [2][15]. - The market is currently in a consolidation phase, with pressures from technical adjustments and funding discrepancies, but the mid-term trend remains positive due to liquidity support [2][15]. Group 2: Stock Performance - Several stocks have achieved significant gains, with six stocks doubling in value within the first month of 2026, including Zhite New Materials, which has seen a rise of 256.35% [4][18]. - Zhite New Materials has been associated with hot concepts such as AI for Science, quantum technology, and commercial aerospace, despite the company clarifying that it has not generated related revenue [6][19]. Group 3: Analyst Ratings and Predictions - As of January 23, 430 companies have received "buy" ratings from various brokerages, with 27 companies having over 50% upside potential based on target prices compared to their latest stock prices [20][21]. - Guizhou Moutai has the highest expected upside, with a target price of 2600 CNY per share, representing a potential increase of 94.02% from its closing price [21][22]. Group 4: Sector Insights - The sectors with high upside potential include electric equipment, biomedicine, electronics, automotive, non-ferrous metals, and liquor, particularly focusing on smart driving, innovative drugs, and artificial intelligence [11][23]. - The liquor industry is expected to benefit from the upcoming Spring Festival marketing activities, with analysts predicting stable sales and a gradual recovery trend [25].